Real time people search
Who is

Abraham Cutler

IL, Chicago, 3316 S Morgan St #2R, 60608


No data available
Find hidden profiles and photos for Abraham Cutler across MySpace, Facebook and 40+ networks.


New Mexico Office of the State Historian : Bairds Ranch Grant
By motion dated December 25, 1862, the Judge, Sydney A. Hubbell, ordered United States Marshal Abraham Cutler to attach Baird's property. On July 23, 1863 ...
Miller Family Connections
Elizabeth Cutler, daughter of Abraham Cutler and Wife-of-Abraham Unknown, May 3, 1564. Children of William4 Miller and Elizabeth Cutler were as follows: 5 i.
Handbuch Der Pflanzenanatomie - A. Fahn, D. David Frederick ...
Fahn, Abraham;Cutler, David F.: Xerophytes. ISBN 978-3-443-14019-9. Introduction 1 Adaptations 1 Arid regions 5 The flora of arid regions 10 Xerophytes 13 ...
Miller - The McNabbs
no date: married Elizabeth Cutler daughter of Abraham Cutler. *1569: son John born. of St. Albans, Hertfordshire, England. *John Miller (son of William and ...
No data available


No data available


No data available



Cutler by name eldest son of Dr. Manasseh Cutler of Hamilton, Mass., had come to the western ... Ewing, Abraham Lenox, John Lenox, James Lenox. Some of ...
LV Hypertrophy - Cutler
Nancy Goldman Cutler, MD. Beaumont Children's Hospital. Royal Oak, Mi .... Abraham, Circulation 2007, 116:2597-2609. Abraham, Circulation 2007, 116: 2597- ...
HISTORY Abraham Morris Rudolph: An Appreciation - Pediatrics
sphere method. In October 2001, Dr Abraham M. Rudolph re- ... Abraham Morris Rudolph was born in Johannes- ..... Cutler JG, Nadas AS, Goodale WT, et al.
Papers of RB Cutler Books Received October 2011 - Baylor University
Abraham. **None Dare Call It Conspiracy (HB). Seattle WA: Double A pub. Political conspir acies. 1983 ... Papers of R. B. Cutler Books Received October 2011 ...
No data available


No data available

Social networks(15)

No data available
No data available
No data available
No data available
No data available
No data available
No data available
No data available
Find hidden profiles and photos for Abraham Cutler across MySpace, Facebook and 40+ networks.




No data available
weight loss diet FDA rejects Vivus fat pill sending shares down Yahoo! News
FDA rejects Vivus' fat pill sending shares down Yahoo! News GAITHERSBURG, Maryland (Reuters) The first new prescription weight-loss pill in more than a decade failed to win backing from U.S. health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds. Shares of Vivus Inc's sank 62 percent on Thursday after U.S. Food and Drug Administration advisers expressed concern the once-a-day pill could cause depression, memory-loss and potential birth defects if used among millions of overweight or obese Americans. Their decision stunned investors, who had more than doubled the share price of the California biotech in the last year on hopes that safety woes would not keep the drug from market. An FDA official was also surprised. When you listen to even the no votes, you got the sense that a lot of people, they weren't strongly against the drug, said Eric Colman, deputy director of FDA's division that oversees such drugs. Shares of rival fat-pill hopefuls, Arena Pharmaceuticals Inc and Orexigen Therapeutics Inc, also sank after the vote. Approving the drug would be a huge public health experiment, said panelist Elaine Morrato of the University of Colorado, one of the 10 panelists who urged against FDA approval. Six others supported the drug, called Qnexa. The FDA will weigh the vote before making its final decision and usually follows its panelists' advice. The panel's rejection is a blow to Vivus, which has not had a U.S. product approved since 1996. Cowen and Co analyst Ian Sanderson said it was possible for Vivus to eventually win U.S. approval, but it would first have to test it in as many as 10,000 patients, at a potential cost of $150 million. They'd need a partner, Sanderson said. The California biotechnology company is seeking the FDA's green light with the hope of beating Arena and Orexigen's rival diet drugs to market. It told FDA's outside experts that Qnexa helped many patients shed 35 to 40 pounds and that its risks were not major. There is little doubt the drug works, panelists said, but potential side effects such as depression, memory loss, increased heart rate and birth defects were a top worry. This medication, in term of efficacy, is far superior than anything that's on the market. The concerns we have are with safety, said Dr. Abraham Thomas of Henry Ford Hospital in Detroit. Panelists were also concerned since patients may take Qnexa for years, but Vivus' data only covered about 12 months. Nearly 70 percent of people in the United States are overweight, and more than a third of them are obese, government statistics show. It's like instant willpower, said Erin Aycock, a clinical trial patient who lost 50 pounds on the drug but later regained most of it. I would do anything to be back on this drug. In a statement after the meeting, Vivus said the panel's vote was disappointing. The company had been expecting FDA's approval decision by October 28. Vivus has said it expects data from a longer, 2-year study by the end of this quarter. Shares of Arena closed down 8.4 percent after the vote, reversing earlier gains. Orexigen closed 10 percent lower. Vivus shares were halted during regular trading on Thursday but fell heavily as they reopened in after-hours trade. Some analysts saw hope for Arena's candidate, lorcaserin, which tentatively faces FDA's advisers September 16 and has 2-year data. Orexigen's FDA panel is expected December 7. (Additional reporting by Ransdell Pierson in New York and Deena Beasley in Los Angeles; Editing by John Wallace, Andre Grenon and Tim Dobbyn) Vivus' weight-loss drug faces key U.S. test Yahoo! News WASHINGTON (Reuters) The first potential U.S. prescription weight-loss pill in more than a decade could move closer to market on Thursday if it can overcome safety hurdles that have plagued diet drugs for years and led to tepid sales despite the growing number of obese Americans. Vivus Inc is seeking Food and Drug Administration support to sell its drug, Qnexa, to adults to use once-a-day along with exercise and diet changes to slim down. On Thursday, a FDA advisory panel will weigh Qnexa the first of three potential new diet drugs and decide whether the benefits of shedding pounds outweigh safety concerns such as the drug's effect on fetuses, mental health and heart rate. The FDA will weigh the panel's recommendation before later making its final decision. Although more than two-thirds of Americans are overweight or obese, weight-loss drugs have not gained much traction. Most only trim a few pounds but carry serious or unpleasant side effects such as heart risks or gas. The critical factor in looking at the data is the enormous benefit that (Qnexa) provides, said Ira Loss, a healthcare analyst for Washington Analysis Corp who follows the FDA for financial clients. The risks are not insurmountable. They can be managed. Last year, prescription and over-the-counter diet drugs took in just $381.5 million in 2009, according to IMS Health. If Qnexa wins the FDA's green light, that could more than double. Analysts estimate Vivus' drug could take in nearly $689 million in sales by 2014, according to consensus forecast data from Thomson Reuters. It would be the second U.S. drug for the biotech, which saw its last drug an erectile dysfunction suppository approved 14 years ago. Its efforts to market a sexual dysfunction cream for women flopped in 2006. Investors, buoyed by the potential for wider sales among millions of overweight Americans (, have been lured to the company. Shares of Vivus have more than doubled in the last year, and are up more than 35 percent so far in 2010. FDA staff have said the company's data clearly shows the drug works and largely meets the agency's new guidelines for obesity drugs issued in 2007. Patients taking Qnexa saw between 3 and 9 percent weight loss over placebo depending on how much of the drug they took, the staff said. They also benefited from improved blood pressure, and better fats and sugar levels in the blood. But first Vivus must convince FDA's panel of outside experts that it does not harbor significant safety issues that have sidelined past options. Qnexa attempts to improve on the infamous fen-phen diet drug. It combines one of fen-phen's ingredients the appetite suppressant phentermine with the anti-seizure drug topiramate. Fen-phen's other ingredient, fenfluramine, was yanked in 1997 when serious heart valve problems emerged. FDA staff earlier this week said they were particularly focused on five potential risks: the potential for congenital defects, psychiatric problems such as depression, memory loss and other cognitive issues, increased body acids, and higher heart rates. I think it's pretty well established that Qnexa has strong efficacy The real question will be how the members of the panel view those safety concerns against the efficacy benefits, Canaccord Adams analyst Adam Cutler told Reuters. The agency plans to ask its panelists to weigh each area of concern before voting on whether to back the drug. FDA officials usually follow their panelists' advice. A decision is expected by October 28. Industry watchers and competitors will also be looking at clues on the FDA's thinking ahead of similar reviews on two rival drugs later this year by Arena Pharmaceuticals and Orexigen Therapeutics. Diet pills already on the market include Abbott Laboratories' Meridia, which carries several heart-related risks, and Roche Holding AG's Xenical, which causes liver problems and uncontrolled bowel movements. Imagine what a drug can do that doesn't have side effects and removes more weight, said Leerink Swann analyst Steve Yoo. On Wednesday, shares of Vivus closed down 2.7 percent at $2.11. Shares of Orexigen closed up more than 11 percent, while Arena closed up nearly 2 percent. (Reporting by Susan Heavey; additional reporting by Susan Kelly in Chicago; Editing by Bernard Orr) Mail this post Technorati Tags: weight loss diet Go to Source Originally posted 2010-08-17 13:17:22. Subscribe to the comments for this post? Share this on Digg this! Post this on Diigo Share this on Facebook Share this on FriendFeed Add this to Google Bookmarks Post on Google Buzz Add this to Google Reader Add this to Mister Wong Share this on Mixx Share this on Reddit Stumble upon something good? Share it on StumbleUpon Share this on Technorati Tweet This! Buzz up!
Translating Dice-K or Matt Kory Offends Multiple Continents In Under 2000 Words
The next time you see Peter Abraham call Carl Crawford a girl or the New York ... In baseball, served as the role of interpreters catcher Jeffrey Cutler, "The last few balls were great ball," and amazingly. I like "urgency" as a synonym for ...
Dean’s list
Burkholder, Crystal L. Butler, Ryan M. Byers, Abraham Cabanilla, Daniel L. Canty, Cherie J. Chism, Blair M. Cillo, Ashley H. Clark, MacKenzie A. Cohick, Tanya N. Cunningham, Rebecca E. Cutler, Michael J. Dance, James W. Daniels, Jonathan C. Decker ...
WEEK AHEAD: Week of good will ahead for children, storm victims, history lovers
His current research interests include public perception of Abraham Lincoln and Civil War tactics ... Tiffany Monique Crosley, Ed Cutler, Sir Charles Davis, James Hardison, Sharon Phennah, Hesta Roach, James Edward White III, and Patricia Woodard.
No data available
No data available
No data available
No data available
No data available

Related people(15)

A Cutler Brandon MB 8
A W Cutler Moody AL 35004
A M Cutler Boise ID 83702
A R Cutler Boise ID 83704
A R Cutler Boise ID 83704
A M Cutler Garden City ID 83714
A Cutler Modesto CA 95355
A Cutler Philadelphia PA 19145
A Cutler Southfield MI 48076
A C Cutler Victoria BC 1
A Cutler Thornhill BC 8
A Cutler Tofino BC 0
A C Cutler Victoria BC 1
A F Cutler Miami FL 33180
A Cutler Providence RI 2905




No data available
Conspiracy Museum
King , Abraham Lincoln , and Ted Kennedy 's Chappaquiddick incident. Cutler's argument was that all these conspiracies can be tied ...
Anne Preven
In 2007, Preven created Check Your Pulse Publishing (CYP) with writer/producers Josh Abraham and Scott Cutler The company, along with ...
The Origins of The Koran: Classic Essays on Islam's Holy Book
Mingana , Arthur Jeffery , David Samuel Margoliouth , Abraham Geiger , William St. Clair Tisdall , Charles Cutler Torrey and Andrew Rippin . ...
Steel Tiger Records
Solid Doctor - with The Heights of Abraham and Mandrillus Sphynx ... Steve Cobby and Dave 'Porky' Brennand record as The Cutler . ...
Lysander Cutler
Lysander Cutler (February 16, 1807 – July 30, 1866) was an American businessman, ... On December 12, 1864, President Abraham Lincoln ...
Hannah Tracy Cutler
Hannah Maria Conant Tracy Cutler (1815–1896) was an abolitionist as well as a ... Cutler consulted repeatedly with Abraham Lincoln before he ...
The Heights of Abraham The Cutler Fila Brazillia | website | current_members Steve Cobby Sim Lister | past_members | notable_instruments ...
List of presidents of Yale University
1 | The Reverend Abraham Pierson | (1641–1707) | (1701–1707) ... 3 | The Reverend Timothy Cutler | (1684–1765) | (1719–1726) 1718/9: ...
Samuel Andrew
predecessor Abraham Pierson | successor Timothy Cutler | alumnus | residence | profession | religion | spouse | children | website | footnotes ...
Church of Jesus Christ (Cutlerite)
This church derives its epithet from its founder, Alpheus Cutler a ... The Book of Abraham is rejected as Scripture, as are the LDS concepts ...